CC Chemours Co

NYSE chemours.com


$ 11.14 $ 0.63 (5.99 %)    

Friday, 21-Nov-2025 13:36:49 EST
QQQ $ 591.27 $ 3.94 (0.67 %)
DIA $ 464.03 $ 4.56 (0.99 %)
SPY $ 660.37 $ 5.32 (0.82 %)
TLT $ 89.36 $ -0.30 (-0.33 %)
GLD $ 375.18 $ 1.24 (0.33 %)
$ 10.48
$ 10.51
$ 11.11 x 65
$ 11.13 x 6
$ 10.51 - $ 11.38
$ 9.01 - $ 21.56
2,483,574
na
1.57B
$ 1.73
nm
TBD
na
na ($ 0.05)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-05-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 02-18-2025 12-31-2024 10-K
5 11-04-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 04-30-2024 03-31-2024 10-Q
8 03-27-2024 12-31-2023 10-K
9 10-27-2023 09-30-2023 10-Q
10 07-28-2023 06-30-2023 10-Q
11 04-28-2023 03-31-2023 10-Q
12 02-10-2023 12-31-2022 10-K
13 10-26-2022 09-30-2022 10-Q
14 07-29-2022 06-30-2022 10-Q
15 05-03-2022 03-31-2022 10-Q
16 02-11-2022 12-31-2021 10-K
17 11-05-2021 09-30-2021 10-Q
18 07-30-2021 06-30-2021 10-Q
19 05-05-2021 03-31-2021 10-Q
20 02-12-2021 12-31-2020 10-K
21 11-04-2020 09-30-2020 10-Q
22 07-31-2020 06-30-2020 10-Q
23 05-06-2020 03-31-2020 10-Q
24 02-14-2020 12-31-2019 10-K
25 11-05-2019 09-30-2019 10-Q
26 08-02-2019 06-30-2019 10-Q
27 05-03-2019 03-31-2019 10-Q
28 02-15-2019 12-31-2018 10-K
29 11-02-2018 09-30-2018 10-Q
30 08-03-2018 06-30-2018 10-Q
31 05-04-2018 03-31-2018 10-Q
32 02-16-2018 12-31-2017 10-K
33 11-03-2017 09-30-2017 10-Q
34 08-03-2017 06-30-2017 10-Q
35 05-03-2017 03-31-2017 10-Q
36 02-17-2017 12-31-2016 10-K
37 11-07-2016 09-30-2016 10-Q
38 08-09-2016 06-30-2016 10-Q
39 05-09-2016 03-31-2016 10-Q
40 02-25-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ubs-maintains-buy-on-chemours-lowers-price-target-to-18

UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Buy and lowers the price target from $21 to $18.

 truist-securities-maintains-buy-on-chemours-lowers-price-target-to-18

Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and lowers the price target from $21 to $18.

 rbc-capital-maintains-outperform-on-chemours-lowers-price-target-to-17

RBC Capital analyst Arun Viswanathan maintains Chemours (NYSE:CC) with a Outperform and lowers the price target from $19 to ...

 chemours-sees-fy2025-sales-5700b-5800b-vs-5882b-est

Chemours (NYSE:CC) sees FY2025 sales of $5.700 billion-$5.800 billion vs $5.882 billion analyst estimate.

 mizuho-maintains-outperform-on-chemours-lowers-price-target-to-18

Mizuho analyst John Roberts maintains Chemours (NYSE:CC) with a Outperform and lowers the price target from $19 to $18.

 ubs-maintains-buy-on-chemours-raises-price-target-to-21

UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Buy and raises the price target from $17 to $21.

 mizuho-maintains-outperform-on-chemours-raises-price-target-to-19

Mizuho analyst John Roberts maintains Chemours (NYSE:CC) with a Outperform and raises the price target from $16 to $19.

 truist-securities-maintains-buy-on-chemours-raises-price-target-to-21

Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and raises the price target from $18 to $21.

 agri-science-giant-corteva-eyes-breakup-to-shield-seed-unit-from-future-risks-report

Corteva is exploring a breakup that would separate its seed and pesticide businesses. The move could reshape agriculture amid f...

 chemours-chair-dawn-farrell-resigns-effective-sept-2-to-lead-canadian-governments-new-major-projects-office

On August 29, 2025, Dawn Farrell, Chair of the Board of Directors (the "Board") of The Chemours Company (the "Compa...

 dupont-divests-aramids-business-in-18-billion-deal-to-sharpen-portfolio

DuPont agreed to sell its Aramids business, including Kevlar and Nomex brands, to Arclin for $1.8B. Deal aligns with DuPont'...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION